Brought to you by 
Aventis co-promotes Byk Gulden's Ciclesonide in US
Apr 2001
Executive Summary
Aventis Pharmaceuticals will co-develop and co-promote in the US Altana's pharmaceuticals subsidiary Byk Gulden's inhaled corticosteroid Ciclesonide for asthma.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aventis co-promotes Byk Gulden's Ciclesonide in US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice